参考文献
PubMed=6203805; DOI=10.20772/cancersci1959.75.2_151
Nakabayashi H., Taketa K., Yamane T., Miyazaki M., Miyano K., Sato J.
Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium.
Gann 75:151-158(1984)
DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)
DOI=10.11418/jtca1981.12.3_221
Namba M., Nakabayashi H., Doi I., Sato J., Miyazaki M.
Cellular characteristics and utilization of human hepatoma cell lines which were established in our laboratory and distributed by Japanese Cancer Research Resources Bank.
Tissue Cult. Res. Commun. 12:221-227(1993)
PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)
PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)
PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::aid-jmv3>3.0.CO;2-A
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-I., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)
DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::aid-mc5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)
PubMed=10523694; DOI=10.3892/or.6.6.1267
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Oncol. Rep. 6:1267-1271(1999)
PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)
PubMed=15708988; DOI=10.1128/JVI.79.5.2689-2699.2005
Sumpter R. Jr., Loo Y.-M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Jr.
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I.
J. Virol. 79:2689-2699(2005)
PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)
PubMed=16935386; DOI=10.1016/j.jhep.2006.05.019
Sun D.-X., Nassal M.
Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.
J. Hepatol. 45:636-645(2006)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=23285155; DOI=10.1371/journal.pone.0052697
Murayama A., Sugiyama N., Yoshimura S., Ishihara-Sugano M., Masaki T., Kim S., Wakita T., Mishiro S., Kato T.
A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest.
PLoS ONE 7:E52697-E52697(2012)
PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)
PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)
PubMed=24973239; DOI=10.1099/vir.0.065995-0
Richter M., Reimann I., Schirrmeier H., Kirkland P.D., Beer M.
The viral envelope is not sufficient to transfer the unique broad cell tropism of Bungowannah virus to a related pestivirus.
J. Gen. Virol. 95:2216-2222(2014)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)
PubMed=27329724; DOI=10.18632/oncotarget.10161
Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J., Murakami Y., Yano H., Kuwano M., Ono M.
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Oncotarget 7:47403-47417(2016)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003
Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.
Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.
Drug Metab. Pharmacokinet. 33:133-140(2018)
PubMed=29774518; DOI=10.1007/s13577-018-0212-3
Kasai F., Hirayama N., Ozawa M., Satoh M., Kohara A.
HuH-7 reference genome profile: complex karyotype composed of massive loss of heterozygosity.
Hum. Cell 31:261-267(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)
PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)
PubMed=32899426; DOI=10.3390/cancers12092510
Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S., Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D., Umu S.U., Rounge T.B., Roessler S., Bermejo J.L.
RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.
Cancers (Basel) 12:2510.1-2510.14(2020)
PubMed=33193621; DOI=10.3389/fgene.2020.546106
Kawamoto M., Yamaji T., Saito K., Shirasago Y., Satomura K., Endo T., Fukasawa M., Hanada K., Osada N.
Identification of characteristic genomic markers in human hepatoma Huh7 and Huh7.5.1-8 cell lines.
Front. Genet. 11:546106.1-546106.10(2020)
PubMed=34320349; DOI=10.1016/j.celrep.2021.109441
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441-109441(2021)
